fda analysis metastatic nsclc treated with antipd-1 therapy past recist用Antipd 1治疗过去再疗法进展.pdfVIP

FDAAnalysis:MetastaticNSCLC

TreatedWithAnti–PD-1Therapy

PastRECISTProgression

CCOtConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016

*CCOisantmedicaleducationcompanythatprovidesstate-of-the-artmedical

informationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.

ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,

Incyte,Merck,andTaihoPharmaceuticals.

Anti–PD-1Therapy